Meeting
2021 ASCO Quality Care Symposium
Scaled integration of FDA approved biosimilars: Closing the knowledge and adoption gaps.
Authors
David Michael Waterhouse
OHC (Oncology Hematology Care)/US Oncology Network, Cincinnati, OH
David Michael Waterhouse, Caleb Burdette, Dan Davies, David R. Drosick, Molly Mendenhall
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cost, Value, and Policy; Health Equity and Disparities; Patient Experience
Track
Cost, Value, and Policy,Technology and Innovation in Quality of Care,Health Care Access, Equity, and Disparities,Patient Experience,Quality, Safety, and Implementation Science
Sub Track
Guideline-Concordant Care Initiatives
Citation
J Clin Oncol 39, 2021 (suppl 28; abstr 15)
DOI
10.1200/JCO.2020.39.28_suppl.15
Abstract #
15
Poster Bd #
A8
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
A successful model of biosimilar adoption in a community oncology practice.
First Author: Lalan S. Wilfong
Poster
2023 ASCO Annual Meeting
Biosimilar uptake and cost savings analysis before and after implementation of a pharmacist-driven substitution program within a National Community Oncology Network: One-year follow-up.
First Author: Melody Chang
Poster
2023 ASCO Annual Meeting
System-wide approach on biosimilars adoption in oncology: Strategic plan on switching and cost savings.
First Author: Suwicha Limvorasak
Poster
2021 ASCO Quality Care Symposium
Evaluation of real-world cost savings and utilization of biosimilar drugs in a community-based oncology practice.
First Author: Amit Sanyal